The influenza treatment market size is expected to see steady growth in the next few years. It will grow to $7.83 billion in 2028 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to the introduction of new antiviral drugs and treatment modalities, expanding vaccination programs, continued expansion and improvement of healthcare infrastructure, increasing elderly population, and development of new treatments. Major trends in the forecast period include progress toward developing universal vaccines, innovations in vaccine delivery systems, integration of AI and big data, advances in personalized medicine, and increased collaborations between pharmaceutical companies.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report
Scope Of Influenza Treatment Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Influenza Treatment Market Overview
Market Drivers –
The increased prevalence of contagious respiratory illnesses is expected to propel the influenza treatment market going forward. Contagious respiratory illness refers to an infectious disease, such as influenza, measles, or respiratory syncytial virus (RSV) infections, transmitted through contact with an infected individual or their bodily fluids, contaminated surfaces, or objects. Factors driving the growth of contagious respiratory illness include higher population densities, inadequate healthcare infrastructure, misuse of antibiotics, and international travel facilitation. Influenza treatment consists of antiviral drugs and vaccinations that are used to treat various contagious respiratory illnesses such as flu, COVID-19, and other respiratory viruses. For instance, in September 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, the rate of hospitalizations linked to RSV (Respiratory Syncytial Virus) surged from 2 hospitalizations per 100,000 people during the week ending August 5, 2023, to 7 hospitalizations per 100,000 individuals by the week concluding on August 19, 2023. Therefore, the increased prevalence of contagious respiratory illnesses is driving the growth of the influenza treatment market.
Market Trends –
Major companies operating in the influenza treatment market are focusing on expanding their product portfolio by adding innovative solutions, such as single-dose oral medicine for influenza treatment, to enhance patient compliance, improve treatment outcomes, and capture a larger market share. A single-dose oral medicine refers to a medication designed to treat influenza (flu) with just one oral dose, simplifying the treatment regimen. For instance, in August 2022, Genentech Inc., a US-based biotechnology company, announced the U.S. Food and Drug Administration (FDA) approval for Xofluza (Baloxavir Marboxil). Xofluza is the first and only single-dose oral medicine that offers a convenient and efficient solution for managing acute uncomplicated influenza in children aged five to less than 12 years who have been symptomatic for no more than 48 hours and other respiratory viruses.
The influenza treatment market covered in this report is segmented –
1) By Product Type: Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, Other Products
2) By Route Of Administration: Oral, Other Routes Of Administration
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels
Get an inside scoop of the influenza treatment market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15832&type=smp
Regional Insights –
North America was the largest region in the influenza treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies –
Major companies operating in the influenza treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc , Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Fujifilm Holdings Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited., Chugai Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Cipla Ltd, Dr. Reddy’s Laboratories Ltd., Lupin Limited, NATCO Pharma Limited, BioCryst Pharmaceuticals Inc., NanoViricides Inc.
Table of Contents
1. Executive Summary
2. Influenza Treatment Market Report Structure
3. Influenza Treatment Market Trends And Strategies
4. Influenza Treatment Market – Macro Economic Scenario
5. Influenza Treatment Market Size And Growth
…..
27. Influenza Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Read Related Topics:
https://goodprnews.com/microsoft-dynamics-services-market-size/
https://goodprnews.com/operations-command-center-market-size/
https://goodprnews.com/polyethylene-glycol-market-size/
https://topprnews.com/microsoft-dynamics-services-market-share/
https://topprnews.com/operations-command-center-market-share/
https://topprnews.com/polyethylene-glycol-market-share/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
